Stephen M Smith

Summary

Publications

  1. ncbi Current clinical treatments of AIDS
    Erin-Margaret Murphy
    Saint Michael's Medical Center, Newark, New Jersey 07102, USA
    Adv Pharmacol 56:27-73. 2008
  2. ncbi MicroRNA profile changes in human immunodeficiency virus type 1 (HIV-1) seropositive individuals
    Laurent Houzet
    Molecular Virology Section, Laboratory of Molecular Microbiology National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
    Retrovirology 5:118. 2008
  3. ncbi Isolation of a new HIV-2 group in the US
    Stephen M Smith
    Division of Infectious Diseases, Saint Michael s Medical Center, Newark, New Jersey 07102, USA
    Retrovirology 5:103. 2008
  4. ncbi The pathogenesis of HIV infection: stupid may not be so dumb after all
    Stephen M Smith
    Saint Michael s Medical Center and The New Jersey Medical School, Newark New Jersey 07102, USA
    Retrovirology 3:60. 2006
  5. ncbi Valproic acid and HIV-1 latency: beyond the sound bite
    Stephen M Smith
    Department of Medicine, Saint Michael s Medical Center, The New Jersey Medical School, Newark, New Jersey 07102, USA
    Retrovirology 2:56. 2005
  6. ncbi Prevalence of GB virus type C in urban Americans infected with human immunodeficiency virus type 1
    Stephen M Smith
    Saint Michael s Medical Center, Newark, New Jersey 07102, USA
    Retrovirology 2:38. 2005
  7. ncbi New York City HIV superbug: fear or fear not?
    Stephen M Smith
    Section of Infectious Diseases, Department of Medicine, Saint Michael s Medical Center, New Jersey, USA
    Retrovirology 2:14. 2005
  8. ncbi Pre-exposure chemoprophylaxis for HIV: it is time
    Stephen M Smith
    Saint Michael s Medical Center and The New Jersey Medical School, Newark, New Jersey 07102, USA
    Retrovirology 1:16. 2004
  9. ncbi HIV CTL escape: at what cost?
    Stephen M Smith
    Saint Michael s Medical Center and The New Jersey Medical School, Newark, New Jersey 07102, USA
    Retrovirology 1:8. 2004
  10. ncbi Retrospective analysis of viral load and SIV antibody responses in rhesus macaques infected with pathogenic SIV: predictive value for disease progression
    S M Smith
    St Michael s Medical Center, Newark, New Jersey 07102, USA
    AIDS Res Hum Retroviruses 15:1691-701. 1999

Collaborators

Detail Information

Publications22

  1. ncbi Current clinical treatments of AIDS
    Erin-Margaret Murphy
    Saint Michael's Medical Center, Newark, New Jersey 07102, USA
    Adv Pharmacol 56:27-73. 2008
  2. ncbi MicroRNA profile changes in human immunodeficiency virus type 1 (HIV-1) seropositive individuals
    Laurent Houzet
    Molecular Virology Section, Laboratory of Molecular Microbiology National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
    Retrovirology 5:118. 2008
    ..The HIV-1-positive individuals were categorized operationally into four classes based on their CD4+ T-cell counts and their viral loads. We report that specific miRNA signatures can be observed for each of the four classes...
  3. ncbi Isolation of a new HIV-2 group in the US
    Stephen M Smith
    Division of Infectious Diseases, Saint Michael s Medical Center, Newark, New Jersey 07102, USA
    Retrovirology 5:103. 2008
    ..Health care providers in Sierra Leone and elsewhere need to be alerted that a subtype of HIV-2, which is not detected by PCR for epidemic HIV-2 strains, exists and can lead to immunosuppression...
  4. ncbi The pathogenesis of HIV infection: stupid may not be so dumb after all
    Stephen M Smith
    Saint Michael s Medical Center and The New Jersey Medical School, Newark New Jersey 07102, USA
    Retrovirology 3:60. 2006
    ..A full understanding of pathogenesis may lead to novel therapies, which preserve the immune system without blocking virus replication...
  5. ncbi Valproic acid and HIV-1 latency: beyond the sound bite
    Stephen M Smith
    Department of Medicine, Saint Michael s Medical Center, The New Jersey Medical School, Newark, New Jersey 07102, USA
    Retrovirology 2:56. 2005
    ..Margolis'group found that valproic acid plus enfuvirtide reduces the pool of CD4+ T-cells, which are latently infected with HIV-1, the so-called viral reservoir. This commentary critically addresses current data on this topic...
  6. ncbi Prevalence of GB virus type C in urban Americans infected with human immunodeficiency virus type 1
    Stephen M Smith
    Saint Michael s Medical Center, Newark, New Jersey 07102, USA
    Retrovirology 2:38. 2005
    ..These data provide increased insight into the prevalence of GBV-C co-infection in the HIV epidemic in this understudied population...
  7. ncbi New York City HIV superbug: fear or fear not?
    Stephen M Smith
    Section of Infectious Diseases, Department of Medicine, Saint Michael s Medical Center, New Jersey, USA
    Retrovirology 2:14. 2005
    ..The Health Commissioner, Thomas R. Frieden, called for increased vigilance against this new strain. Is this situation an emerging crisis or simply an unusual case report of rapid HIV progression?..
  8. ncbi Pre-exposure chemoprophylaxis for HIV: it is time
    Stephen M Smith
    Saint Michael s Medical Center and The New Jersey Medical School, Newark, New Jersey 07102, USA
    Retrovirology 1:16. 2004
    ..An effective vaccine and widespread treatment are years, if not, decades away. In this most urgent situation, I propose that pre-exposure chemoprophylaxis be studied as a means to reduce the spread of HIV-1 among at-risk individuals...
  9. ncbi HIV CTL escape: at what cost?
    Stephen M Smith
    Saint Michael s Medical Center and The New Jersey Medical School, Newark, New Jersey 07102, USA
    Retrovirology 1:8. 2004
    ..Further, a CTL based HIV-1 vaccine is likely to have long-term protective effect against disease only if the escape virus is significantly weakened compared with wild type...
  10. ncbi Retrospective analysis of viral load and SIV antibody responses in rhesus macaques infected with pathogenic SIV: predictive value for disease progression
    S M Smith
    St Michael s Medical Center, Newark, New Jersey 07102, USA
    AIDS Res Hum Retroviruses 15:1691-701. 1999
    ..We also found that a formalin-fixed, microencapuslated SIV vaccine reduced viral load without affecting clinical outcome. This latter finding may have implications for the evaluation of HIV-1 human vaccine trials...
  11. ncbi Estrogen protects against vaginal transmission of simian immunodeficiency virus
    S M Smith
    Infectious Diseases Section, Dept of Internal Medicine, St Michael s Medical Center, Newark, NJ 07102, USA
    J Infect Dis 182:708-15. 2000
    ..Moreover, topical vaginal estrogen therapy may be an effective means of reducing HIV vaginal transmission in these high-risk groups...
  12. ncbi HIV vaccine development in the nonhuman primate model of AIDS
    Stephen M Smith
    Saint Michael s Medical Center and The New Jersey Medical School UMDNJ, Newark, NJ, USA
    J Biomed Sci 9:100-11. 2002
    ..Much of this work has been done with the nonhuman primate model of AIDS. In a historical context, vaccine studies, which use this model, are summarized and discussed...
  13. ncbi A peptide-loaded dendritic cell based cytotoxic T-lymphocyte (CTL) vaccination strategy using peptides that span SIV Tat, Rev, and Env overlapping reading frames
    Zachary Klase
    Department of Infectious Diseases, Saint Michael s Medical Center, Newark, New Jersey, USA
    Retrovirology 3:1. 2006
    ..However, conclusive in vivo control of a challenge inoculation of SIVmac239 was not observed suggesting that CTL epitopes within densely overlapping reading frames are also subject to escape mutations...
  14. ncbi Topical estrogen protects against SIV vaginal transmission without evidence of systemic effect
    Stephen M Smith
    Saint Michael's Medical Center and The New Jersey Medical School, Newark, New Jersey 07102, USA
    AIDS 18:1637-43. 2004
    ..These results support the study of topical vaginal estriol in preventing HIV vaginal transmission in at-risk women...
  15. ncbi An in vivo replication-important function in the second coding exon of Tat is constrained against mutation despite cytotoxic T lymphocyte selection
    Stephen M Smith
    Saint Michael s Medical Center, Newark, New Jersey 07102, USA
    J Biol Chem 278:44816-25. 2003
    ..We suggest the second coding exon of Tat as an example of a functionally constrained "epitope" whose elicited CTL response cannot be escaped by virus mutation without producing a virus that replicates poorly in vivo...
  16. ncbi HIV vaccine development
    Mahender Singh
    Saint Michael's Medical Center, Newark, New Jersey 07102, USA
    Front Biosci 10:2064-81. 2005
    ..This review discusses current results obtained in the macaque model and human vaccine trials...
  17. ncbi The evolution of HIV and its consequences
    Cristian Apetrei
    Tulane National Primate Research Center and Department of Tropical Medicine, Tulane University Health Sciences Center, Covington, LA 70433, USA
    Infect Dis Clin North Am 18:369-94. 2004
    ..The potential impact of this viral diversity on treatment, monitoring,and vaccine development is discussed...
  18. ncbi Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis
    Jeffrey P Nadler
    Hillsborough County Health Department, University of South Florida, Tampa, FL 33602, USA
    AIDS 21:F1-10. 2007
    ....
  19. ncbi Women have a greater immunological response to effective virological HIV-1 therapy
    Diana G Finkel
    AIDS 17:2009-11. 2003
  20. ncbi Measuring brain atrophy in multiple sclerosis
    Nicola De Stefano
    Department of Neurological and Behavioural Sciences, University of Siena, Italy
    J Neuroimaging 17:10S-15S. 2007
    ..It represents one of most promising in vivo measures of neuroaxonal degeneration in MS, and it should be used extensively in the future to assess and monitor pathological evolution and treatment efficacy in this disease...
  21. ncbi Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy
    Valerie L Stevenson
    NMR Research Unit, Institute of Neurology, London
    J Neurol 249:171-7. 2002
    ....
  22. ncbi High- and low-tech malaria control
    Stephen M Smith
    Science 304:1744; author reply 1744. 2004